Introduction
obesity, cancers, neuropsychiatric disorders, AUD, liver cirrhosis
DISORDER, OBESITY, DISEASE, LIVER CIRRHOSIS, TYPE 2 DIABETES
Alcohol use disorder (AUD) affects approximately 5% of people worldwide and is considered a key risk factor for noncommunicable disease, such as a variety of cancers, neuropsychiatric disorders, and liver cirrhosis (There are currently 4 approved pharmacological treatments for AUD, and though these substances display favorable effects in some studies (Glucagon-like peptide-1 (GLP-1) agonists have been used in the treatment of type 2 diabetes and obesity due to their incretin and anorexigenic effects. The fact that they reduce appetite has led researchers to investigate their effect on brain circuits that regulate the motivational properties of drugs of abuse. GLP-1–producing neurons in the CNS (The sole randomized trial in patients with AUD found no group difference regarding reduction in heavy drinking days, but functional MRI (fMRI) cue reactivity and dopamine transporter availability were significantly decreased in the exenatide group compared with placebo (We previously conducted a randomized placebo-controlled trial that investigated whether the GLP-1 agonist dulaglutide increased abstinence rates from nicotine during smoking cessation (